{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:29:00Z","timestamp":1780950540214,"version":"3.54.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Gordon and Llura Gund Foundation"},{"name":"Edmond C. Lynch Jr. Cancer Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"DOI":"10.1093\/infdis\/jiab538","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T03:37:14Z","timestamp":1634355434000},"page":"187-189","source":"Crossref","is-referenced-by-count":4,"title":["Clofazimine for Babesiosis: Preclinical Data Support a Clinical Trial"],"prefix":"10.1093","volume":"225","author":[{"given":"Edouard","family":"Vannier","sequence":"first","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Gelfand","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"2022011804285562700_CIT0001","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-96-5-601","article-title":"Successful chemotherapy of transfusion babesiosis.","volume":"96","author":"Wittner","year":"1982","journal-title":"Ann Intern Med"},{"key":"2022011804285562700_CIT0002","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1056\/NEJM200011163432004","article-title":"Atovaquone and azithromycin for the treatment of babesiosis.","volume":"343","author":"Krause","year":"2000","journal-title":"N Engl J Med"},{"key":"2022011804285562700_CIT0003","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2022011804285562700_CIT0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/ciab050","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis.","volume":"72","author":"Krause","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022011804285562700_CIT0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12941-017-0198-9","article-title":"Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone.","volume":"16","author":"Kletsova","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2022011804285562700_CIT0006","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients.","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2022011804285562700_CIT0007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/649859","article-title":"Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.","volume":"50","author":"Wormser","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022011804285562700_CIT0008","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix477","article-title":"Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia.","volume":"65","author":"Simon","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022011804285562700_CIT0009","article-title":"Combination of clofazimine and atovaquone as a potent therapeutic regimen for the radical cure of Babesia microti infection in immunocompromised hosts.","author":"Tuvshintulga","journal-title":"J Infect Dis"},{"key":"2022011804285562700_CIT0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/1791013a0","article-title":"A new series of phenazines (rimino-compounds) with high antituberculosis activity.","volume":"179","author":"Barry","year":"1957","journal-title":"Nature"},{"key":"2022011804285562700_CIT0011","doi-asserted-by":"crossref","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"2022011804285562700_CIT0012","doi-asserted-by":"crossref","first-page":"ofx147","DOI":"10.1093\/ofid\/ofx147","article-title":"Clofazimine in nontuberculous mycobacterial infections: a growing niche.","volume":"4","author":"McGuffin","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2022011804285562700_CIT0013","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20151519","article-title":"Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone.","volume":"213","author":"Lawres","year":"2016","journal-title":"J Exp Med"},{"key":"2022011804285562700_CIT0014","doi-asserted-by":"crossref","first-page":"16079","DOI":"10.1038\/nmicrobiol.2016.79","article-title":"A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse.","volume":"1","author":"Lemieux","year":"2016","journal-title":"Nat Microbiol"},{"key":"2022011804285562700_CIT0015","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","article-title":"Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.","volume":"286","author":"Yano","year":"2011","journal-title":"J Biol Chem"},{"key":"2022011804285562700_CIT0016","doi-asserted-by":"crossref","first-page":"E7073","DOI":"10.1073\/pnas.1521988112","article-title":"Antiinfectives targeting enzymes and the proton motive force.","volume":"112","author":"Feng","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011804285562700_CIT0017","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/infdis\/jiaa195","article-title":"Clofazimine, a promising drug for the treatment of Babesia microti infection in severely immunocompromised hosts.","volume":"222","author":"Tuvshintulga","year":"2020","journal-title":"J Infect Dis"},{"key":"2022011804285562700_CIT0018","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/23744235.2016.1164339","article-title":"Infection with Babesia microti in humans with non-specific symptoms in North East Poland.","volume":"48","author":"Moniuszko-Malinowska","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"2022011804285562700_CIT0019","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1089\/vbz.2016.1946","article-title":"First report of Babesia microti-caused babesiosis in Spain.","volume":"16","author":"Arsuaga","year":"2016","journal-title":"Vector Borne Zoonotic Dis"},{"key":"2022011804285562700_CIT0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12864-016-3225-x","article-title":"Babesia microti from humans and ticks hold a genomic signature of strong population structure in the United States.","volume":"17","author":"Carpi","year":"2016","journal-title":"BMC Genomics"},{"key":"2022011804285562700_CIT0021","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab538\/41319938\/jiab538.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/2\/187\/42224131\/jiab538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/2\/187\/42224131\/jiab538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T04:29:54Z","timestamp":1642480194000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/2\/187\/6401697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2022,1,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab538","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,15]]},"published":{"date-parts":[[2021,10,19]]}}}